LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
TABLE OF CONTENTS
1. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY
OUTLOOK
5.1. BRAZIL
5.2. MEXICO
5.3. REST
OF LATIN AMERICA
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE
LIST
TABLE 1: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS
MATRIX
TABLE 3: VENDOR SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 6: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 7: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 8: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 9: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028
(IN $ MILLION)
TABLE 10: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
FIGURE
LIST
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT
ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021
& 2028 (IN %)
FIGURE 6: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 8: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 9: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN
%)
FIGURE 10: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD,
2022-2028 (IN $ MILLION)
FIGURE 11: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO
MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028
(IN $ MILLION)
FIGURE 13: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021
& 2028 (IN %)
FIGURE 14: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $
MILLION)
FIGURE 15: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $
MILLION)
FIGURE 16: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2021 & 2028 (IN %)
FIGURE 17: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST,
2022-2028 (IN $ MILLION)
FIGURE 18: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION
TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 19: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 20: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING,
2022-2028 (IN $ MILLION)
FIGURE 21: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 22: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $
MILLION)
FIGURE 23: LATIN
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028
(IN $ MILLION)
FIGURE 24: LATIN
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2021 & 2028 (IN %)
FIGURE 25: BRAZIL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 26: MEXICO
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 27: REST OF
LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
(IN $ MILLION)
Growing efforts to generate public awareness are beneficial
for the market’s growth
MARKET OUTLOOK
Triton Market Research
has put forth that the Alzheimer’s disease therapeutics and diagnostics market
in Latin America is likely to grow with a 6.19% of CAGR over the forecast years
from 2022-2028. Mexico, Brazil, and Rest of Latin America are analyzed in the
market in this region.
In 2019, a major
international initiative for Alzheimer’s disease led by the School of Medicine at
Washington University opened five new sites in the region, including Brazil,
Argentina, Mexico, and Colombia. The objective was to conduct research &
development activities on Alzheimer’s disease.
Further, there are a number
of academic research groups and non-governmental organizations (NGOs) engaged
in Alzheimer’s disease-related research. The Brazilian Association of Alzheimer’s
(ABRAz), which is a leading national NGO, offers support to families of
patients affected by dementia. The nation has also managed to gain the
attention of private healthcare insurance-providing companies.
Besides, a number of
workshops and programs are being held across the country for understanding
Alzheimer’s disease management. For instance, a UK-Brazil dementia workshop,
held in 2019, revealed that the nation faces a major challenge of
underdiagnosis of Alzheimer’s disease and dementia. This highlights the immense
need for awareness, diagnosis, and treatment of Alzheimer’s disease in the
country, and, in turn, is expected to drive the market growth.
Get more insights the Latin America Alzheimer’s Disease
Therapeutics And Diagnostic Market:
COMPETITIVE OUTLOOK
Merck and Co, Lupin
Limited, F. Hoffmann-La Roche AG, Pfizer Inc, Zydus Cadila, Johnson and
Johnson, Sun Pharmaceuticals Industries Ltd, Novartis AG, and Baxter
International Inc are some of the prominent names operating in the Alzheimer’s
disease therapeutics and diagnostics market.
SEGMENTATION
1. BAXTER
INTERNATIONAL INC
2. F.
HOFFMANN-LA ROCHE AG
3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
4. NOVARTIS
AG
5. PFIZER
INC
6. SIEMENS
HEALTHINEERS AG
7. AMARANTUS
BIOSCIENCE HOLDINGS INC
8. EISAI
CO LTD
9. ELI
LILLY & COMPANY
10. LUPIN
LIMITED
11. MERCK
AND CO
12. BIOGEN
INC
13. COGNOPTIX
INC
14. GE
HEALTHCARE
15. JOHNSON
AND JOHNSON
16. SUN
PHARMACEUTICALS INDUSTRIES LTD
17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
18. ZYDUS
CADILA
Comments
Post a Comment